For the year ending 2025-12-31, CTNM had $53,660K increase in cash & cash equivalents over the period. -$55,543K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -59,978 |
| Depreciation and amortization | 323 |
| Non-cash operating lease expense | 1,080 |
| Stock-based compensation | 10,038 |
| Accretion of premiums/discounts on marketable securities, net | 791 |
| Loss (gain) on sale of property and equipment | -67 |
| Change in fair value of warrant liability | 0 |
| Gain on marketable securities | 12 |
| Prepaid expenses and other current assets | 3,396 |
| Other long-term assets | -3 |
| Accounts payable | -869 |
| Accrued expenses | -516 |
| Operating lease liabilities | -1,261 |
| Net cash used in operating activities | -55,312 |
| Purchase of property and equipment | 231 |
| Proceeds from sale of equipment | 0 |
| Purchases of marketable securities | 162,502 |
| Sales and maturities of marketable securities | 159,020 |
| Net cash used in investing activities | -3,713 |
| Proceeds from issuance of common stock-IPO | 0 |
| Payments of deferred offering costs | 256 |
| Proceeds from issuance of common stock-At The Market Offering | 19,012 |
| Proceeds from issuance of common stock-Follow On Offering | 93,243 |
| Proceeds from exercise of stock options | 219 |
| Proceeds from employee stock purchase plan | 467 |
| Net cash provided by financing activities | 112,685 |
| Net increase in cash and cash equivalents | 53,660 |
| Cash and cash equivalents at beginning of year | 21,943 |
| Cash and cash equivalents at end of year | 75,603 |
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)